

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1096R1

Serial No.

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Raju

Filing Date

23 Jun 1998

Group

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
PSS	1	5,047,335	10.09.91	Paulson et al.	-	-	JCS18 U.S. PTO 09/102865 06/23/98
	2	5,096,816	17.03.92	Maiorella	-	-	
	3	5,116,964	26.05.92	Capon et al.	-	-	
	4	5,278,299	11.01.94	Wong et al.	-	-	
	5	5,510,261	23.04.96	Goochee et al.	-	-	
	6	5,565,335	15.10.96	Capon et al.	-	-	
	7	5,610,297	11.03.97	Powers	-	-	

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
PSS	8	WO 92/20798	26.11.92	PCT WO	-	-		
	9	WO 94/11026	26.05.94	PCT WO	-	-		
	10	WO 95/19181	20.07.95	PCT WO	-	-		
	11	WO 95/23865	08.09.95	PCT WO	-	-		
	12	WO 96/30046	03.10.96	PCT WO	-	-		
	13	WO 97/30087	21.08.97	PCT WO	-	-		

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

PSS	14	Abraham et al., "p55 Tumor Necrosis Factor Receptor Fusion Protein in the Treatment of Patients With Severe Sepsis and Septic Shock" <u>Journal of the American Medical Assn.</u> 277:1531-1538 (1997)
	15	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin" <u>Proc. Natl. Acad. Sci.</u> 88:10535-10539 (1991)
	16	Beale et al., "Structure and function of the constant regions of immunoglobulins" <u>Quarterly Reviews of Biophysics</u> 9:135-180 (1976)
	17	Boeggeman et al., "Expression of deletion constructs of bovine β -1,4-galactosyltransferase in Escherichia coli: importance of Cys134 for its activity" <u>Protein Engineering</u> 6:779-785 (1993)
	18	Bolt et al., "The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties" <u>European Journal of Immunology</u> 23:403-411 (1993)
	19	Borman, "Carbohydrates' Complexities: Glycobiologists attain a more detailed understanding of the involvement of carbohydrates in intricate life processes" <u>C&EN</u> 74:36-40 (1996)
	20	Borys et al., "Ammonia Affects the Glycosylation Patterns of Recombinant Mouse Placental Lactogen-I By Chinese Hamster Ovary Cells in a pH-Dependent Manner" <u>Biotechnology and Bioengineering</u> 43:505-514 (1994)
	21	Borys et al., "Culture pH Affects Expression Rates and Glycosylation of Recombinant Mouse Placental Lactogen Proteins by Chinese Hamster Ovary (CHO) Cells" <u>Bio/Technology</u> 11:720-724 (1993)
	22	Boyd et al., "The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of campath-1H" <u>Molecular Immunology</u> 32:1311-1318 (1995)
	23	Cant et al., "Glycosylation and functional activity of anti-D secreted by two human lymphoblastoid cell lines" <u>Cytotechnology</u> 15:223-228 (1994)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1096R1

Serial No.

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Raju

Filing Date

23 Jun 1998

Group

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

24	Carter et al., "Humanization of an anti-p185 ^{HER2} antibody for human cancer therapy" <u>Proc. Natl. Acad. Sci.</u> 89:4285-4289 (1992)
25	Chatterjee et al., "Analysis of the Sequences of Human β -1,4-Galactosyltransferase cDNA Clones" <u>Int. J. Biochem Cell. Biol.</u> 27:329-336 (1995)
26	Chotigeat et al., "Role of Environmental Conditions on the Expression Levels, Glycoform Pattern and Levels of Sialyltransferase for hFSH Produced by Recombinant CHO cells" <u>Cytotechnology</u> 15:217-221 (1994)
27	Chuang et al., "Elimination of N-linked glycosylation sites from the human IgA1 constant region: effects on structure and function" <u>Journal of Immunology</u> 158:724-732 (1997)
28	Cox et al., "Effect of Media Composition on the Induction of Chorionic Gonadotropin by Sodium Butyrate in HeLa Cells" <u>In Vitro</u> 19(1):1-6 (1983)
29	Donadel et al., "Human polyreactive and monoreactive antibodies: effect of glycosylation on antigen binding" <u>Glycobiology</u> 4:491-496 (1994)
30	Duncan et al., "The binding site for Clq on IgG" <u>Nature</u> 332:738-740 (1988)
31	Fischer et al., "Reduction of Graft Failure by a Monoclonal Antibody (Anti-LFA-1 CD11a) After HLA Nonidentical Bone Marrow Transplantation in Children with Immunodeficiencies, Osteopetrosis, and Fanconi's Anemia" <u>Blood</u> 77(2):249-256 (January 15, 1991)
32	Gazzano-Santoro et al., "A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody" <u>Journal of Immunological Methods</u> 202:163-171 (1997)
33	Goochee et al., "The Oligosaccharides of Glycoproteins: Bioprocess Factors Affecting Oligosaccharide Structure and Their Effect on Glycoprotein Properties" <u>Bio/Technology</u> 9:1347-1355 (1991)
34	Goochee et al., "The Oligosaccharides of Glycoproteins: Factors Affecting Their Synthesis and Their Influence on Glycoprotein Properties" <u>Frontiers in Bioprocessing II: Proceedings of Frontiers in Biochemistry II</u> (Boulder, Colorado, June 17-21 1990) pps. 199-240 (1992)
35	Harris et al., "Refined Structure of an Intact IgG2a Monoclonal Antibody" <u>Biochemistry</u> 36:1581-1597 (1997)
36	Hart, "Glycosylation" <u>Current Opinion in Cell Biology</u> 4:1017-1023 (1992)
37	Hayter et al., "Glucose-Limited Chemostat Culture of Chinese Hamster Ovary Cells Producing Recombinant Human Interferon- γ " <u>Biotechnology and Bioengineering</u> 39:327-335 (1992)
38	Hearing et al., "Isolation of Chinese Hamster Ovary Cell Lines Temperature Conditional for the Cell-Surface Expression of Integral Membrane Glycoproteins" <u>The J. of Cell Biology</u> 108:339-353 (1989)
39	Herrmann et al., "Large-Scale Production of a Soluble Human β -1,4-Galactosyltransferase Using a <i>Saccharomyces cerevisiae</i> Expression System" <u>Protein Expr. Purif.</u> 6:72-78 (1995)
40	Hourmant et al., "Administration of an Anti-CD11a Monoclonal Antibody in Recipients of Kidney Transplantation" <u>Transplantation</u> 58(3):377-380 (August 1994)
41	Hsu et al., "A Comparative Study of the Peroxidase-antiperoxidase Method and an Avidin-biotin Complex Method for Studying Polypeptide Hormones with Radioimmunoassay Antibodies" <u>Am. J. Clin. Path.</u> 75(5):734-738 (May 1981)
42	Hsu et al., "Differential N-Glycan Patterns of Secreted and Intracellular IgG Produced in <i>Trichoplusia ni</i> Cells" <u>The Journal of Biological Chemistry</u> 272:9062-9070 (1997)
43	Iwase et al., "Estimation of the Number of O-Linked Oligosaccharides per Heavy Chain of Human Serum IgA1 by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOFMS) Analysis of the Hinge Glycopeptide" <u>J. Biochemistry</u> 120:393-397 (1996)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1096R1

Serial No.

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Raju

Filing Date

23 Jun 1998

Group

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

44	Jefferis et al., "Glycosylation of Antibody Molecules: Structural and Functional Significance" <u>Antibody Engineering</u> 65:111-128 (1997)
45	Jefferis et al., "Recognition sites on human IgG for Fcγ receptors: the role of glycosylation" <u>Immunology Letters</u> 44:111-117 (1995)
46	Jenkins et al., "Getting the glycosylation right: Implications for the biotechnology industry" <u>Nature Biotechnology</u> 14:975-981 (1996)
47	Kaminski et al., "Radioimmunotherapy of B-cell Lymphoma with [¹³¹ I]Anti-B1 (Anti-CD20) Antibody" <u>New England J. of Medicine</u> 329:459-465 (1993)
48	Kim et al., "The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies" <u>Growth Factors</u> 7(1):53-64 (1992)
49	Kleene et al., "Expression of Soluble Active Human β _{1,4} Galactosyltransferase in <i>Saccharomyces cerevisiae</i> " <u>Biochem. & Biophys. Res. Comm.</u> 201:160-167 (1994)
50	Kotz et al., "Immunoglobulin G galactosylation deficiency determined by isoelectric focusing and lectin affino blotting in differential diagnosis of rheumatoid arthritis" <u>Electrophoresis</u> 17:533-534 (1996)
51	Kumpel et al., "Galactosylation of Human IgG Monoclonal Anti-D Produced by EBV-transformed B-lymphoblastoid Cell Lines is Dependent on Culture Method and Affects Fc Receptor-mediated Functional Activity" <u>Hum. Antibod. Hybridomas</u> 5:143-151 (1994)
52	Le Gros et al., "The Effects of Sodium Butyrate on Lymphokine Production" <u>Lymphokine Research</u> 4(3):221-227 (1985)
53	Liu et al., "Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity" <u>J. Immunol.</u> 139:3521-3526 (1987)
54	Malhotra et al., "Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein" <u>Nat. Med.</u> 1:237-243 (1995)
55	Maloney et al., "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients With Recurrent B-Cell Lymphoma" <u>Blood</u> 84:2457-2466 (1994)
56	McLaughlin et al., "Preliminary Report on a Phase III Pivotal Trial of the Anti-CD20 Antibody (MAB) IDEC-C2B8 in Patients (PTS) with Relapsed Low-Grade or Follicular Lymphoma (LG/F NHL)" <u>Proc. Am. Soc. Clin. Oncol.</u> 15:417 (1996)
57	Mizutani et al., "High Glucose and Hyperosmolarity Increase Platelet-derived Growth Factor mRNA Levels in Cultured Human Vascular Endothelial Cells" <u>Biochemical and Biophysical Research Communications</u> 187(2):664-669 (1992)
58	Ohlson et al., "Use of monoclonal antibodies for weak affinity chromatography" <u>Journal of Chromatography A</u> 758:199-208 (1997)
59	Parekh, "Effects of Glycosylation on Protein Function" <u>Current Opinion in Structural Biology</u> 1:750-754 (1991)
60	Parekh et al., "Cell-Type-Specific and Site-Specific N-Glycosylation of Type I and Type II Human Tissue Plasminogen Activator" <u>Biochemistry</u> 28:7644-7662 (1989)
61	Park et al., "Enhanced β-Galactosidase Production by High Cell-Density Culture of Recombinant <i>Bacillus subtilis</i> with Glucose Concentration Control" <u>Biotechnology and Bioengineering</u> 40:686-696 (1992)
62	Press et al., "Radiolabeled-antibody Therapy of B-cell Lymphoma with Autologous Bone Marrow Support" <u>New England J. of Medicine</u> 329:1219-1224 (1993)
63	Presta et al., "Humanization of an Antibody Directed Against IgE" <u>J. Immunol.</u> 151(5):2623-2632 (September 1, 1993)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Att'y Docket No.

P1096R1

Serial No.

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Raju

Filing Date

23 Jun 1998

Group	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
1	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

[illegible]

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Serial No.
09/102,865

Applicant
Raju

Filing Date
23 Jun 1998

Group ~~1633~~ 1644

[illegible]

Date Considered

USCOMM-DC 80-398.